TP53 and acute kidney injury: In May 2018, a phase III multi-center trial is designed to evaluate p53 siRNA versus placebo for the prevention of Major Adverse Kidney Events (MAKE) in subjects at high risk for acute kidney injury following cardiac surgery (208).